Evidence map›Paper›PMID 33061293›Full record

ArticleDrug design, development and therapy2020

Phoenixin 14 Inhibits High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Experimental Mice.

Fan Yang, Ping Huang, Liandong Shi, Feng Liu, Aimei Tang, Shaohui Xu

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Drug design, development and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06891586 (Investigation of the Relationship Between Phoenixin-14 Levels and Echocardiographic Findings in Infants of Diabetic Mothers), which is not on this map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06891586 nacompletednot on this mapstarted 2024, after this paper: background citation

Investigation of the Relationship Between Phoenixin-14 Levels and Echocardiographic Findings in Infants of Diabetic Mothers

TypeinterventionalSponsorKonya City HospitalRan2024 to 2026Enrolled84ConditionsNewborn Morbidity, Newborn ComplicationArmsechocardiographic evaluation and blood phoenixin-14 level
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 33 citations in OpenAlex.

  1. Renoprotective Potential of Nateglinide in an Acute Kidney Injury Model.International journal of molecular sciences · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. The Levels of Phoenixin-14 and Phoenixin-20 in Patients with Type 2 Diabetes Mellitus.Endocrine, metabolic & immune disorders drug targets · 2024
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Regulation and physiological functions of phoenixin.Frontiers in molecular biosciences · 2022
    Review
  16. Investigation of serum phoenixin levels in patients with hypertension.Revista da Associacao Medica Brasileira (1992) · 2022
    Article
  17. Article
  18. Review
  19. Phoenixin: More than Reproductive Peptide.International journal of molecular sciences · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fan YangDepartment of Endocrinology, Guilin People's Hospital, Guilin, Guangxi 541002, People's Republic of China.ORCID 0000-0002-8748-5180
Ping HuangDepartment of Endocrinology, Guilin People's Hospital, Guilin, Guangxi 541002, People's Republic of China.
Liandong ShiDepartment of Ultrasonography, Guilin People's Hospital, Guilin, Guangxi 541002, People's Republic of China.
Feng LiuDepartment of Ministry of Health Care, Guilin People's Hospital, Guilin, Guangxi 541002, People's Republic of China.
Aimei TangDepartment of Ministry of Health Care, Guilin People's Hospital, Guilin, Guangxi 541002, People's Republic of China.
Shaohui XuDepartment of Endocrinology, Guilin People's Hospital, Guilin, Guangxi 541002, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionNonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases. The development of NAFLD is closely associated with hepatic lipotoxicity, inflammation, and oxidative stress. The new concept of NAFLD treatment is to seek molecular control of lipid metabolism and hepatic redox hemostasis. Phoenixin is a newly identified neuropeptide with pleiotropic effects. This study investigated the effects of phoenixin 14 against high-fat diet (HFD)-induced NAFLD in mice. MATERIALS AND

methodsFor this study, we used HFD-induced NAFLD mice models to analyze the effect of phonenixin14. The mice were fed on HFD and normal diet and also given phoenixin 14 (100 ng/g body weight) by gastrogavage for 10 weeks. The peripheral blood samples were collected for biochemical assays. The liver tissues were examined for HFD-induced tissue fibrosis, lipid deposition and oxidative activity including SOD, GSH, and MDA. The liver tissues were analyzed for the inflammatory cytokines and oxidative stress pathway genes.

resultsThe results indicate that phoenixin 14 significantly ameliorated HFD-induced obesity and fatty liver. The biochemical analysis of blood samples revealed that phoenixin 14 ameliorated HFD-induced elevated circulating alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol, and triglyceride levels, suggesting that phoenixin 14 has a protective role in liver function and lipid metabolism. Hematoxylin-eosin (HE) and Oil Red O staining of the liver showed that phoenixin 14 alleviated HFD-induced tissue damage and lipid deposition in the liver. Furthermore, the mice administered with phoenixin 14 had increased hepatic SOD activity, increased production of GSH and reduced MDA activity, as well as reduced production of TNF-α and IL-6 suggesting that phoenixin 14 exerts beneficial effects against inflammation and ROS. The findings suggest an explanation of how mechanistically phoenixin 14 ameliorated HFD-induced reduced activation of the SIRT1/AMPK and NRF2/HO-1 pathways.

conclusionCollectively, this study revealed that phoenixin 14 exerts a protective effect in experimental NAFLD mice. Phoenixin could be of the interest in preventive modulation of NAFLD.

Indexed as

Non-alcoholic Fatty Liver DiseasePeptidesAdministration, OralAnimalsCytokinesDiet, High-FatDisease Models, AnimalFatty LiverMaleMembrane ProteinsMiceMice, Inbred C57BLMitochondrial ProteinsObesityOxidative StressCytokinesMembrane ProteinsMitochondrial ProteinsPeptidesSmim20 protein, mouseinflammationNAFLDnonalcoholic fatty liver diseaseNRF2/HO-1oxidative stressphoenixin 14SIRT1/AMPK

Identifiers

PMID33061293
PMCPMC7519838
OpenAlexW3087273048

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.